Table 3:
Quantitative Acceptability Data from Surveys Administered to Adolescents. Pain during Injection Questionnaire (FACES Scale)
| Pain during Injection Questionnaire (FACES Scale) | Cohort 1Ca | Cohort 1Rb | TOTAL | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Week 4 (N=29) n(%) |
Week 8 (N=29) n(%) |
Week 12c (N=8) n(%) |
Week 4 (N=23) n(%) |
Week 8 (N=23) n(%) |
Week 12 (N=13) n(%) |
Week 4 (N=52) n(%) |
Week 8 (N=52) n(%) |
Week 12 (N=21) n(%) |
|
| No hurt | 12 (41) | 9 (31) | 6 | 4 (17)d | 3 (13) | 3 | 16 (31) | 12 (23) | 9 (43) |
| Hurts little bit | 13 (45) | 15 (52) | 1 | 14 (61) | 11 (48) | 4 | 27 (52) | 26 (50) | 5 (24) |
| Hurts little more | 2 (7) | 4 (14) | 1 | 1 (4) | 6 (26) | 4 | 3 (6) | 10 (19) | 5 (24) |
| Hurts even more | 2 (7) | 1 (3) | 0 | 3 (13) | 2 (9) | 2 | 5 (10) | 3 (6) | 2 (10) |
| Hurts whole lot | 0 | 0 | 0 | 1 (4) | 1 (4) | 0 | 1 (2) | 1 (2) | 0 |
| Hurts worst | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
a
Cohort 1C consisted of participants assigned to receive long-acting cabotegravir injections.
b
Cohort 1R consisted of participants assigned to receive long-acting rilpivirine injections.
c
Only participants enrolled in Protocol Version 2.0 received a Week 12 injection.
d
Percent values given in parentheses may not add up to 100 due to rounding.